TITLE

WUXI PHARMATECH

AUTHOR(S)
Investor's Business Daily
PUB. DATE
November 2013
SOURCE
Investors Business Daily;11/13/2013, pA02
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the report of Chinese medical research outsourcer Wuxi Pharmatech which reveals \ per share (EPS) of the company has obtained 17% increase for the third quarter (Q3) of 2013.
ACCESSION #
91938527

 

Related Articles

  • WUXI PHARMATECH. Investor's Business Daily // Investors Business Daily;11/13/2014, pA02 

    The article reports that Chinese medical contract researcher Wuxi Pharmatech Inc. has posted an increase in earnings per share in the third quarter of 2014 due to the significant increase in sales.

  • WUXI PHARMATECH. Investor's Business Daily // Investors Business Daily;3/6/2015, pA02 

    The article reports on the statement of the open-access research and development (R&D) services provider Wuxi Pharmatech regarding increase of its diluted earnings per American depositary shares (ADS) by 4% to 55 cents in the fourth quarter (Q4) of 2014.

  • WuXi Beats, Guidance Light. Investor's Business Daily // Investors Business Daily;3/ 6/2014, pA01 

    7 Chinese drug and biotech outsourcer

  • Wuxi Pharmatech. Investor's Business Daily // Investors Business Daily;8/19/2014, pA02 

    The article reports on an announcement by Wuxi Pharmatech Inc. regarding the passing of the U.S. Food and Drug Administration (FDA) inspection by its Shanghai SynTheAll Pharmaceutical subsidiary.

  • BofA, JPM Arrange $1.25B CF for Pharma Acquisition. Kellerhals, Richard // High Yield Report;5/3/2010, Vol. 21 Issue 18, p9 

    The article reports on a 1.26 billion U.S.-dollar credit facility arranged by the banks Bank of America Merrill Lynch and JP Morgan for the acquisition of WuXi PharmaTech by fellow pharmaceutical research company Charles River Labs.

  • WuXi PharmaTech, PRA Form Chinese Market JV.  // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p87 

    The article reports on the joint venture agreement of WuXi PharmaTech Inc. and PRA to offer clinical trial services in China, Hong Kong and Macau.

  • Acetaminophen deal.  // Chemical Week;1/29/97, Vol. 159 Issue 4, p48 

    Reports on A.F. Pharmaceuticals' contract as exclusive distributor of Wuxi C.S.I. Pharmaceutical's acetaminophen product.

  • WUXI PHARMATECH. Investor's Business Daily // Investors Business Daily;5/15/2014, pA02 

    The article reports on the financial performance of Wuxi PharmaTech Inc. for the first quarter (Q1) 2014 which indicates a 14% decline in stock prices.

  • WuXi PharmaTech, PBI In Biomarker Alliance.  // Contract Pharma;Apr2014, Vol. 16 Issue 3, p36 

    The article reports on the collaboration between research and development (R&D) services company WuXi PharmaTech and biomarker laboratory services provider Pacific Biomarkers (PBI), in which the latter will provide validated biomarker assays for the clinical trial testing services of WuXi.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics